Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 6, 2025 -- Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin-resistant tuberculosis, according to a study published in the Jan. 30 issue of the New England Journal of Medicine.
Lorenzo Guglielmetti, M.D., Ph.D., from Médecins Sans Frontières in Paris, and colleagues conducted a phase 3, multinational, noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis to five nine-month oral regimens, including combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). A total of 754 participants were randomly assigned to one of five combinations or standard therapy; 699 were included in the modified intention-to-treat analysis and 562 were included in the per-protocol analysis. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was −12 percentage points.
The researchers found that 80.7 percent of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. In the modified intention-to-treat population, the risk difference between standard therapy and each of the four new regimens was noninferior: 9.8, 8.3, 4.6, and 2.5 percentage points for BCLLfxZ, BLMZ, BDLLfxZ, and DCMZ, respectively. In the per-protocol population, the differences were similar, apart from DCMZ, which was not noninferior. Across the regimens, the proportion of participants with grade 3 or higher adverse events was similar.
"The results of this trial support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis," the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Health Officials Alarmed by Tuberculosis Outbreak in Kansas
TUESDAY, Jan. 28, 2025 -- Kansas health officials are tackling the largest tuberculosis (TB) outbreak in U.S. history, with 67 confirmed cases since the start of 2025. The...
Shorter Treatment Regimens Recommended for Tuberculosis
MONDAY, Jan. 13, 2025 -- In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and...
Global TB Cases Hit Record High, TB Becomes Top Infectious Disease Killer
WEDNESDAY, Oct. 30, 2024 -- The World Health Organization reports that tuberculosis (TB) cases hit a record high in 2023, with more than 8 million diagnoses and 1.25 million...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.